Tumor Electric Fields Treatment System for Glioblastoma

Overview

This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.

Full Title of Study: “A Prospective, Single-center, Single-arm, Exploratory Study on the Treatment of Recurrent Glioblastoma With Tumor Electric Fields Treatment System”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Device Feasibility
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2021

Detailed Description

Subjects who have previously completed radiotherapy and at least two cycles of chemotherapy with imaging or pathological evidence of tumor recurrence will receive Tumor Electric Fields Treatment System. The main objective is to evaluate the safety of applying the Tumor Electric Fields Treatment System to subjects with recurrent GBM.

Interventions

  • Device: Tumor Electric Fields Treatment System
    • Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.

Arms, Groups and Cohorts

  • Experimental: Tumor Electric Fields Treatment System
    • Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.

Clinical Trial Outcome Measures

Primary Measures

  • The treatment-related adverse events
    • Time Frame: 12 months
    • Number of patients who experienced a treatment-related adverse event.
  • Time to Progression
    • Time Frame: 12 months
    • Time to progression of patients with recurrent glioblastoma.
  • Overall Survival Rate
    • Time Frame: 12 months
    • Number of patients alive at 12 months.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with pathological diagnosis of glioblastoma at first surgery (WHO Grade IV, supratentorial location); – Age between 18 and 65 years, male or female; – Previously completed radiotherapy and at least two cycles of chemotherapy; – With imaging or pathological evidence of tumor recurrence; – Karnofsky performance score (KPS) score ≥ 70 before intervention; – With a life expectancy more than 3 months; – Adopted effective contraceptive measures at child-bearing age; – Provided written informed consent. Exclusion Criteria:

  • Patients unwilling to use the equipment ≥ 18h per day; – With poor compliance or live too far from the research center, who cannot keep regular follow-up or adjust the electrode position of the treatment equipment, and who refuse to receive follow-up to terminal survival; – With poor healing of scalp wound, poor scalp condition, large skull defect or other cases where electrodes are not suitable for wearing; – Within 3 months from radiotherapy; – Within 4 weeks from the last cycle of chemotherapy; – Within 4 weeks from surgery for recurrence; – Participated in other clinical trials. – Pregnant; – Epilepsy symptoms not effectively controlled; – Blood and biochemical indicators in the following range: A. Liver function impairment: AST or ALT > 3 times the upper limit of normal; B. Total bilirubin> upper limit of normal value; C. Renal impairment: serum creatinine>1.7mg /dL (>150 mol/L); D. Coagulopathy: PT or APTT >1.5 times normal; E. Platelets counts < 100×10^9/L; F. Absolute neutrophils count < 1×10^9/L; G. Hemoglobin < 100g/L; – With severe infectious diseases, such as acute severe infection and HIV positive; – Other conditions, such as an implanted cardiac pacemaker or deep brain stimulator, severe intracranial edema, increased intracranial pressure resulting in midline shift>5mm, clinically significant papilledema, or reduced level of consciousness, allergy to conductive coupling agent, gel, and other serious life-threatening diseases. – Other circumstances considered inappropriate to participate in the research by the investigator.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xiangya Hospital of Central South University
  • Collaborator
    • Hunan An Tai Kang Cheng Biotechnology Co., Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Zhixiong Liu, M.D., +8613607318785, zhixiongliu@csu.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.